| Index | Recent Threads | Unanswered Threads | Who's Active | Guidelines | Search |
 |
World Community Grid Forums
Category: Active Research
Forum: Mapping Cancer Markers Forum
Thread: Interesting News Articles About Cancer |
| No member browsing this thread |
|
Thread Status: Active Total posts in this thread: 530
|
|
| Author |
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 665 Status: Offline Project Badges: 
|
Racial Disparities in the Molecular Landscape of Cancer
African-Americans (AA) have the highest incidence and mortality of any racial/ethnic group in the US for most cancer types. Researchers report in ANTICANCER RESEARCH International Journal of Cancer Research and Treatment, April 2018, vol. 38, no 4, 2235-2240, that their data revealed significant differences and trends in molecular signatures of the three cancer types, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and high-grade glioma (HGG), in African-American (AA) and Caucasian (CC) cohorts. These findings imply that there may be differences in carcinogenesis between AA and CC patients and that race should be considered regarding cancer incidence and outcome. https://www.ncbi.nlm.nih.gov/pubmed/29599344?dopt=Abstract  |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 665 Status: Offline Project Badges:
|
A cancer drug tailored to your tumor? Experts trade barbs over 'precision oncology'
For people with advanced cancer who are running out of options, many cancer centers now offer this hope: Have your tumor's genome sequenced, and doctors will match you with a drug that targets its weak spot. But this area of cancer treatment has critics, who say its promise has been oversold. Last week, two prominent voices in the field faced off in a sometimes-tense debate on what's often called precsion oncology at the annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois. Their dispute threw a splash of cold water on a meeting packed with sessions on genome-based cancer treatment. http://www.sciencemag.org/news/2018/04/cancer...s-over-precision-oncology |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 665 Status: Offline Project Badges:
|
Has Precision Oncology Been Over-Promised?
The ides of precision cancer therapies targeting a patient's cancer genome may have been oversold, according to Vinay Prasad, an oncologist from the Oregon Health Science University in Portland. Arguing against him was oncologist David Hyman from the Memorial Sloan Kettering Cancer Centre in New York. Ultimately, the pair did not reach a consensus on the practicality and promise of precision oncology, although there were some points of agreement. http://www.frontlinegenomics.com/news/22159/h...ology-been-over-promised/ |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
Diagnosing breast cancer with a pill that makes tumors glow
"To take imaging down to the molecular level, the researchers designed an oral pill that can deliver a fluorescent dye to [malignant] tumors in breast tissue. Once there, doctors can perform an infrared scan on the breast, and the dye will cause cancerous cells to reflect the light." https://newatlas.com/breast-cancer-pill-diagnosis/54450/ The 4:11 minute video explains it simply. Currently experimental only, tested in mice. Full paper, no paywall: "Oral Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic Mouse Model for Breast Cancer Screening" https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.7b00994 |
||
|
|
Jim1348
Veteran Cruncher USA Joined: Jul 13, 2009 Post Count: 1066 Status: Offline Project Badges: 
|
Scientists like Liu are eager to find an accurate blood test that would offer a cheaper and more convenient way to diagnose and track cancer growth. While existing blood exams look for changes that can indicate cancer, they don’t isolate tumor cells, he said. He has applied for a patent so that he can one day sell the devices to hospitals. In the past year, he partnered with LVHN to move the device from his laboratory to doctors’ offices. Doctors then will analyze patients’ blood samples to see if tumor cell counts match CT scans showing progression or regression of the disease, explained Dr. Suresh Nair, medical director of LVHN Cancer Institute. “Just because we’ve been doing scans for the last 30 years doesn’t mean we have to keep doing it,” Nair said. http://www.mcall.com/business/healthcare/mc-n...nosis-20180425-story.html |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 665 Status: Offline Project Badges:
|
Genomic databases weakened by lack of non-European populations
Greater diversity in genomic databases will advance precision medicine Precision medicine will largely be built on vast troves of genomic information, but diverse populations are still underrepresented in public genomic databases, according to a new study by researchers from the National Institutes of Health and Partners Healthcare/Harvard Medical School. They found significantly fewer studies of African, Latin-American and Asian ancestral populations compared to European populations in two Genomic databases, the Genome-Wide Association Study Catalog (GWAS) and the database of Genotypes and Phenotypes (dbGaP). Findings were published in the May 7 issue of Health Affairs. https://www.genome.gov/27571370/2018-news-fea...-noneuropean-populations/ |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
Nanoparticles carry drug duo to fight Glioblastoma brain cancer
"Glioblastoma is one of the most deadly forms of cancer. Affecting the brain, those unlucky enough to receive a diagnosis don't have many treatment options – and usually a median life expectancy of just over a year. Now, researchers at MIT have developed nanoparticles that could provide hope, crossing the blood-brain barrier and delivering two types of drugs to fight tumors. The MIT nanoparticles are liposomes, fatty droplets that can carry one drug on the inside and another in the outer layer. On the inside, the particles were loaded with a common chemotherapy drug called temozolomide, while the outer shell contained a more experimental substance known as JQ-1. This partnership was very carefully chosen. Temozolomide is widely known to damage the DNA of cancer cells, while JQ-1 is a type of bromodomain inhibitor, meaning it reduces the tumor's ability to repair that DNA damage. To help the nanoparticles sneak through the blood-brain barrier, the researchers coated them with a protein called transferrin, which also has the bonus effect of helping the liposomes bind to the cancer cells. And finally, the whole package was coated in a polymer called polyethylene glycol (PEG), which protects the nanoparticles from being attacked by the immune system." Much more at https://newatlas.com/nanoparticles-brain-cancer/54770/ |
||
|
|
Glen David Short
Senior Cruncher Joined: Nov 6, 2008 Post Count: 185 Status: Offline Project Badges: 
|
Blood test could lead to early detection of lung cancer https://interestingengineering.com/blood-test...-detection-of-lung-cancer
---------------------------------------- |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 665 Status: Offline Project Badges:
|
Tailoring cancer treatment to genetic profile extends lives, study finds
A long-term 'precision medicine' study found improved outcomes when doctors engage in genetic sequencing of patient's tumors The study was presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, the world's largest gathering of cancer specialists. https://tinyurl.com/yahoub5z |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 665 Status: Offline Project Badges:
|
CRISPR stocks tank after research shows edited cells might cause cancer
Gene editing tool CRISPR-Cas9 has been hailed as a breakthrough that could allow scientists to treat and possibly even cure genetic diseases. In two studies published Monday in the journal Nature Medicine , researchers found editing cells' genomes with the technique might increase the risk of cancer. Those edited cells are those ones that are intended to treat diseases. http://www.cnbc.com/2018/06/11/crispr-stocks-...s-might-cause-cancer.html |
||
|
|
|